M. S. Diamond

A single intranasal dose of ChAd-SARS-CoV-2-S vaccine prevents SARS-CoV-2 infection and likely confers sterilizing immunity in mice.

This study evaluates the association between SARS-CoV-2 neutralizing antibodies and results from three commercial serological assays, finding moderate correlations and varying agreement rates.

The paper describes synthetic monoclonal antibodies that neutralize SARS-CoV-2 by binding to the spike protein and blocking ACE2 receptor interaction, showing potent antiviral activity.

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

This study shows SARS-CoV-2 infects human intestinal enterocytes via TMPRSS2 and TMPRSS4, but viral particles in stool are inactivated, suggesting limited fecal-oral transmission.

The paper shows that PIKfyve kinase inhibitors block infection by Zaire ebolavirus and SARS-CoV-2 by preventing viral content release.

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.